Ashraf Z. Badros, MBCHB
Professor of Medicine
UM Faculty Physicians, Inc.
Available for Telehealth Visits
Dr. Badros has extensive clinical experience in Bone Marrow Transplantation with special interest in multiple myeloma. He was involved in the initial trails of thalidomide and has conducted many clinical trials for treatment of relapsed and refractory multiple myeloma. Dr. Badros research has focused on evaluation of immunological approaches to eradicate residual myeloma cells in the high-risk setting following autologous stem cell transplantation using natural killer (NK) and interleukin -2 (IL-2) activated cells and non-myeloablative allogeneic donor grafts.
Dr. Badros is involved in the development of targeted novel therapeutics. He has completed a gene therapy trial using G-3039 ""Bcl-antisense."" He evaluated the use of the proteosome inhibitor ""bortezomib"" in the newly diagnosed myeloma patients and evaluated the effects of bortezomib on stem cell. Currently, Dr. Badros is evaluating various combinations of novel therapies in multiple myeloma such as Lenalidomide and histone deacetylase inhibitors (SAHA) in relapsed myeloma patients alone and in combinations with dexamethasone and/or bortezomib.
Board Certification and EducationToggle accordion item
Ain Shams University Faculty of Medicine, 1986
New York Downtown Hospital, 1990
Ain Shams University Faculty of Medicine, 1987
Harbor Hospital, 1993
Ain Shams University Faculty of Medicine, 1989
Roswell Park Cancer Institute - Hematology/Oncology, 1994
Georgetown University Medical Center - Oncology, 1996
American Board of Internal Medicine - Medical Oncology, 1995
Hospital AffiliationsToggle accordion item
University of Maryland Medical Center